⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Devi PierceMD

Internal Medicine · Corydon, IN 47112

NPI: 1144218496

Share:

21

🟡 Moderate

ML Fraud Detection Score: 98%

Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.

Learn more →

Risk Flags

Elevated antipsychotic prescribing (65+)Opioid + benzodiazepine co-prescriberExtreme fills per patient

Risk indicators are statistical patterns, not allegations. Learn more

14,659

Total Claims

$1.3M

Drug Cost

412

Beneficiaries

$3,133

Cost/Patient

Risk Score Breakdown 21/100

Low (0)Moderate (15)Elevated (30)High (50+)
Opioid + benzodiazepine combo+8
Elderly antipsychotic prescribing+5
High fills per patient+5

Score components are additive. Read full methodology

Peer Comparison vs. 110,156 Internal Medicine providers

+293%

Opioid rate vs peers

8.8% vs 2.2% avg

+122%

Cost per patient vs peers

$3,133 vs $1,411 avg

+6%

Brand preference vs peers

11.3% vs 10.6% avg

⚠️ Opioid + Benzodiazepine Co-Prescriber

This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.

🔎 Data Overview

🤖

Our machine learning model — trained on 281 confirmed fraud cases — gives this provider a "Very High" fraud-pattern score. All 20 decision trees in our ensemble model agree that this provider's prescribing patterns resemble those of confirmed fraud cases. This is a statistical finding, not an accusation.

💊

Opioid rate is 293% above Internal Medicine peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.

⚠️

This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

8.8%

Opioid Rate

1,289

Opioid Claims

$34K

Opioid Cost

4.8%

Long-Acting Rate

Brand vs Generic

89% generic

Brand: 1,641 claims · $954K

Generic: 12,929 claims · $332K

Top Prescribed Drugs

Drug (Generic)ClaimsCost
Empagliflozin127$120K
Semaglutide62$73K
Apixaban88$72K
Insulin Glargine,hum.Rec.Anlog55$54K
Fluticasone/Vilanterol69$43K
Linaclotide54$43K
Sitagliptin Phosphate31$40K
Fluticasone/Umeclidin/Vilanter38$35K
Rifaximin12$35K
Budesonide/Formoterol Fumarate52$33K
Dulaglutide27$31K
Rivaroxaban35$31K
Tiotropium Bromide38$30K
Mirabegron33$25K
Celecoxib176$21K

Prescribing Profile

188

Unique Drugs

$275K

IRA Negotiated Drugs

$105K

GLP-1 Drugs

21.0

Anomaly Score

Patient Profile

69

Avg Age

61%

Female

1.39

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data